Management

William K. Heiden, CEO

Mr. Heiden has served as our President, Chief Executive Officer and as a director since September 2004. Prior to joining Elixir, Mr. Heiden served as President and Chief Operating Officer from May 2002 responsible for corporate strategy and overseeing all operations of PRAECIS, a public biopharmaceutical company which was subsequently purchased by GlaxoSmithKline. Mr. Heiden was recruited to PRAECIS from the Schering Plough Corporation which he joined in 1987 in their executive development program, and held positions of increasing responsibility for a variety of businesses in the U.S. and abroad. Mr. Heiden is a member of the board of directors of LFB, S.A., a French biotechnology company and is a member of the Duke University Healthcare Advisory Council. Mr. Heiden holds an M.B.A. from Cornell University's Johnson Graduate School of Management, an M.A. from the University of Louvain and a B.S. from the University of Florida.

Gregory D. Perry, Chief Finance Officer

Mr. Perry has served as our Chief Financial Officer and Executive Vice President since January 2007. Prior to joining Elixir, Mr. Perry served as Chief Financial Officer of Domantis, Ltd., a biopharmaceutical company that was recently acquired by GlaxoSmithKline, which he joined in June 2006. From May 2003 to August 2005, Mr. Perry served as Senior Vice President and Chief Financial Officer at Transkaryotic Therapies. At Domantis and Transkaryotic Therapies, Mr. Perry was responsible for overseeing all aspects of accounting, finance, planning, taxation and investor relations. Prior to Transkaryotic Therapies, Mr. Perry served as Senior Vice President, Finance and Business Development, Life Sciences at PerkinElmer Inc. where he was responsible for their financial operations. Mr. Perry holds a B.A. from Amherst College.

Peter S. DiStefano, Ph.D., Chief Scientific Officer

Dr. DiStefano has served as our Chief Scientific Officer and Vice President since October 2001. Prior to joining us, Dr. DiStefano was Senior Director of Neurobiology at Millennium Pharmaceuticals from 1997 to 2001, focusing on central nervous system disorders, pain and urology. From 1991 to 1997, he was senior Staff Scientist at Regeneron Pharmaceuticals where he was responsible for research and clinical development activities for peripheral nervous system disorders. Dr. DiStefano started his career in 1986 in the Neuroscience division at Abbott Laboratories. He is co-author of over 100 scientific publications in leading journals and holds more than 10 issued patents. Dr. DiStefano received his B.A. from Kenyon college, a Ph.D. in Pharmacology from Upstate Medical Center in Syracuse and post-doctoral training at Washington University School of Medicine.

Paul M. Martha, M.D., Chief Medical Officer

Dr. Martha has served as our Chief Medical Officer and Senior Vice President since October 2007. Prior to joining us, Dr. Martha served as Executive Vice President of Research and Development at Chiasma, Inc., a privately-held biopharmaceutical company, which he joined in March 2007. Prior to joining Chiasma, Dr. Martha served as the Chief Medical Officer and Senior Vice President of Shire Human Genetic Therapies, formerly Transkaryotic Therapies, Inc., which he joined in January 2004. At Transkaryotic Therapies, Inc., Dr. Martha focused on clinical development activities, culminating in successful FDA and EMEA product submissions and approvals. From November 2000 to December 2003, Dr. Martha served as Chief Medical and Regulatory Officer at Interleukin Genetics, Inc. and prior to that has held other industry positions at companies including Genentech, Inc. and has served on the faculties of Tufts University School of Medicine and The University of Virginia School of Medicine. He is co-author of over 50 scientific publications in leading journals. Dr. Martha holds a B.S.in Biology from Trinity College and an M.D. from the University of Connecticut, School of Medicine.

[ back to top ]